1.Treatment Principles and Paradigm of Diabetic Microvascular Complications Responding Specifically to Traditional Chinese Medicine
Anzhu WANG ; Xing HANG ; Lili ZHANG ; Xiaorong ZHU ; Dantao PENG ; Ying FAN ; Min ZHANG ; Wenliang LYU ; Guoliang ZHANG ; Xiai WU ; Jia MI ; Jiaxing TIAN ; Wei ZHANG ; Han WANG ; Yuan XU ; .LI PINGPING ; Zhenyu WANG ; Ying ZHANG ; Dongmei SUN ; Yi HE ; Mei MO ; Xiaoxiao ZHANG ; Linhua ZHAO
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(5):272-279
To explore the advantages of traditional Chinese medicine (TCM) and integrative TCM-Western medicine approaches in the treatment of diabetic microvascular complications (DMC), refine key pathophysiological insights and treatment principles, and promote academic innovation and strategic research planning in the prevention and treatment of DMC. The 38th session of the Expert Salon on Diseases Responding Specifically to Traditional Chinese Medicine, hosted by the China Association of Chinese Medicine, was held in Beijing, 2024. Experts in TCM, Western medicine, and interdisciplinary fields convened to conduct a systematic discussion on the pathogenesis, diagnostic and treatment challenges, and mechanism research related to DMC, ultimately forming a consensus on key directions. Four major research recommendations were proposed. The first is addressing clinical bottlenecks in the prevention and control of DMC by optimizing TCM-based evidence evaluation systems. The second is refining TCM core pathogenesis across DMC stages and establishing corresponding "disease-pattern-time" framework. The third is innovating mechanism research strategies to facilitate a shift from holistic regulation to targeted intervention in TCM. The fourth is advancing interdisciplinary collaboration to enhance the role of TCM in new drug development, research prioritization, and guideline formulation. TCM and integrative approaches offer distinct advantages in managing DMC. With a focus on the diseases responding specifically to TCM, strengthening evidence-based support and mechanism interpretation and promoting the integration of clinical care and research innovation will provide strong momentum for the modernization of TCM and the advancement of national health strategies.
2.Mechanisms of Core Compound Formula and Compatibility of Traditional Chinese Medicine Components for Prevention and Treatment of Chronic Atrophic Gastritis Based on Huazhuo Jiedu Therapy
Fan GAO ; Xiaoxuan MO ; Fengyue XU ; Jiaye TIAN ; Xinmeng ZHAO ; Jianming JIANG ; Qiuhong GUO
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(21):51-64
ObjectiveTo reveal the compatibility rules of the core compound formula and traditional Chinese medicine (TCM) components for prevention and treatment of chronic atrophic gastritis (CAG) by Huazhuo Jiedu (turbidity-resolving and detoxifying) therapy through uniform design in view of the potential regulatory pathway of endogenous turbid-toxin retention in CAG, elucidate the potential pathway by which the compound formulas regulate the Wnt/β-catenin-connexin 43 (CX43) signaling axis, demonstrated the efficacy enhancement and toxicity attenuation among the components, thus providing experimental evidence for the scientific application of multi-component, multi-target compatibility in TCM compound formulas. MethodsA mouse model of CAG was established with N-methyl-N-nitrosourea (MNU). Sixty mice were randomly allocated into 5 groups (n=12 per group): blank control, model, low-dose Huazhuo Jiedu core compound formula (HXFF-L, 4.004 g·kg-1), high-dose Huazhuo Jiedu core compound formula (HXFF-H, 8.008 g·kg-1), and positive control (folic acid at 11 mg·kg-1 + vitamin B12 at 14 mg·kg-1). The therapeutic efficacy and molecular mechanism of the core compound formula were evaluated by hematoxylin-eosin (HE) staining, Alcian blue-periodic acid-Schiff (AB-PAS) staining, enzyme-linked immunosorbent assay (ELISA), transmission electron microscopy (TEM), immunofluorescence assay, and Western blot. The chemical components of the core compound formula were detected and effective components were screened by ultra-high performance liquid chromatography coupled with quadrupole-orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS). Another 120 mice were randomized into blank control, model, and 8 HXFF component-combination groups with different dosages (uniform design groups 1-8, n=12 per group). A uniform design was adopted, with pathological scores of mouse gastric tissue as well as serum levels of pepsinogen Ⅰ (PGⅠ), pepsinogen Ⅱ (PGⅡ), and gastrin 17 (GAS17) set as dependent variables. Multivariate linear regression analysis was performed to predict the optimal proportion of core components in the compound formula and explore its compatibility rules. ResultsPharmacodynamic validation showed that compared with the blank control group, the model group had decreased gastric weight index (P<0.01) and increased pathological damage score and inflammatory factor levels (P<0.01). Compared with the model group, these indicators were reversed in the HXFF-L, HXFF-H, and positive control groups (P<0.05, P<0.01). Immunofluorescence results showed that CX43 expression was downregulated in the model group compared with the blank control group (P<0.01) and upregulated in the HXFF-H and positive control groups compared with the model group (P<0.05, P<0.01). Western blot results showed that compared with the blank control group, the model group demonstrated upregulated protein levels of Wnt and β-catenin in the gastric tissue (P<0.01). Compared with those in the model group, the protein level of Wnt was downregulated in the HXFF-L, HXFF-H, and positive control groups (P<0.05, P<0.01), while that of β-catenin was downregulated only in the HXFF-H group (P<0.05). A total of 25 compounds were identified in the core compound formula, including 9 from Coptidis Rhizoma, 10 from Pogostemonis Herba, 2 from Scorpio, and 4 from Lilii Bulbus. According to the category and origin of compounds, Coptidis Rhizoma alkaloids, Pogostemonis Herba volatile oils, Scorpio peptides, and Lilii Bulbus alkaloids were finally selected for component research. The predicted optimal combination of TCM components was as follows: Coptidis Rhizoma alkaloids at 75 mg·kg-1, Pogostemonis Herba volatile oils at 2.25 mg·kg-1, Scorpio protein extract at 90 mg·kg-1, and Lilii Bulbus alkaloids at 9 mg·kg-1. Coptidis Rhizoma alkaloids, Scorpio protein extract, Pogostemonis Herba volatile oils, and Lilii Bulbus alkaloids can ameliorate pathological lesions of the gastric tissue. Scorpio protein extract exerted positive regulatory effects on the gastric function, while Pogostemonis Herba volatile oils and Lilii Bulbus alkaloids showed negative correlations with partial gastric function indicators. Further investigations are required to clarify their dose-effect relationships and safety profiles. ConclusionThis study, for the first time, predicts the optimal proportion and synergistic regulatory mechanism of the core compound formula of Huazhuo Jiedu therapy, revealing the synergistic compatibility logic of its components. It provides a novel strategy for the precise TCM treatment of CAG and the modern development of compound formulas.
3.Mechanisms of Core Compound Formula and Compatibility of Traditional Chinese Medicine Components for Prevention and Treatment of Chronic Atrophic Gastritis Based on Huazhuo Jiedu Therapy
Fan GAO ; Xiaoxuan MO ; Fengyue XU ; Jiaye TIAN ; Xinmeng ZHAO ; Jianming JIANG ; Qiuhong GUO
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(21):51-64
ObjectiveTo reveal the compatibility rules of the core compound formula and traditional Chinese medicine (TCM) components for prevention and treatment of chronic atrophic gastritis (CAG) by Huazhuo Jiedu (turbidity-resolving and detoxifying) therapy through uniform design in view of the potential regulatory pathway of endogenous turbid-toxin retention in CAG, elucidate the potential pathway by which the compound formulas regulate the Wnt/β-catenin-connexin 43 (CX43) signaling axis, demonstrated the efficacy enhancement and toxicity attenuation among the components, thus providing experimental evidence for the scientific application of multi-component, multi-target compatibility in TCM compound formulas. MethodsA mouse model of CAG was established with N-methyl-N-nitrosourea (MNU). Sixty mice were randomly allocated into 5 groups (n=12 per group): blank control, model, low-dose Huazhuo Jiedu core compound formula (HXFF-L, 4.004 g·kg-1), high-dose Huazhuo Jiedu core compound formula (HXFF-H, 8.008 g·kg-1), and positive control (folic acid at 11 mg·kg-1 + vitamin B12 at 14 mg·kg-1). The therapeutic efficacy and molecular mechanism of the core compound formula were evaluated by hematoxylin-eosin (HE) staining, Alcian blue-periodic acid-Schiff (AB-PAS) staining, enzyme-linked immunosorbent assay (ELISA), transmission electron microscopy (TEM), immunofluorescence assay, and Western blot. The chemical components of the core compound formula were detected and effective components were screened by ultra-high performance liquid chromatography coupled with quadrupole-orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS). Another 120 mice were randomized into blank control, model, and 8 HXFF component-combination groups with different dosages (uniform design groups 1-8, n=12 per group). A uniform design was adopted, with pathological scores of mouse gastric tissue as well as serum levels of pepsinogen Ⅰ (PGⅠ), pepsinogen Ⅱ (PGⅡ), and gastrin 17 (GAS17) set as dependent variables. Multivariate linear regression analysis was performed to predict the optimal proportion of core components in the compound formula and explore its compatibility rules. ResultsPharmacodynamic validation showed that compared with the blank control group, the model group had decreased gastric weight index (P<0.01) and increased pathological damage score and inflammatory factor levels (P<0.01). Compared with the model group, these indicators were reversed in the HXFF-L, HXFF-H, and positive control groups (P<0.05, P<0.01). Immunofluorescence results showed that CX43 expression was downregulated in the model group compared with the blank control group (P<0.01) and upregulated in the HXFF-H and positive control groups compared with the model group (P<0.05, P<0.01). Western blot results showed that compared with the blank control group, the model group demonstrated upregulated protein levels of Wnt and β-catenin in the gastric tissue (P<0.01). Compared with those in the model group, the protein level of Wnt was downregulated in the HXFF-L, HXFF-H, and positive control groups (P<0.05, P<0.01), while that of β-catenin was downregulated only in the HXFF-H group (P<0.05). A total of 25 compounds were identified in the core compound formula, including 9 from Coptidis Rhizoma, 10 from Pogostemonis Herba, 2 from Scorpio, and 4 from Lilii Bulbus. According to the category and origin of compounds, Coptidis Rhizoma alkaloids, Pogostemonis Herba volatile oils, Scorpio peptides, and Lilii Bulbus alkaloids were finally selected for component research. The predicted optimal combination of TCM components was as follows: Coptidis Rhizoma alkaloids at 75 mg·kg-1, Pogostemonis Herba volatile oils at 2.25 mg·kg-1, Scorpio protein extract at 90 mg·kg-1, and Lilii Bulbus alkaloids at 9 mg·kg-1. Coptidis Rhizoma alkaloids, Scorpio protein extract, Pogostemonis Herba volatile oils, and Lilii Bulbus alkaloids can ameliorate pathological lesions of the gastric tissue. Scorpio protein extract exerted positive regulatory effects on the gastric function, while Pogostemonis Herba volatile oils and Lilii Bulbus alkaloids showed negative correlations with partial gastric function indicators. Further investigations are required to clarify their dose-effect relationships and safety profiles. ConclusionThis study, for the first time, predicts the optimal proportion and synergistic regulatory mechanism of the core compound formula of Huazhuo Jiedu therapy, revealing the synergistic compatibility logic of its components. It provides a novel strategy for the precise TCM treatment of CAG and the modern development of compound formulas.
4.Analysis of clinical phenotype and genetic variant in a patient with De-differentiated liposarcoma.
Jingjing AO ; Feicheng YANG ; Yuzhong YANG ; Jia TIAN ; Chenjia LU ; Xiaoying LIU ; Zhe ZHANG ; Wenxiu YANG ; Chunjian MO
Chinese Journal of Medical Genetics 2025;42(6):741-746
OBJECTIVE:
To explore the clinical characteristics and genetic etiology of a patient with De-differentiated liposarcoma (DDLPS).
METHODS:
A 38-year-old female patient with DDLPS who had visited Hunan Provincial People's Hospital in January 2025 was selected as the study subject. A retrospective study method was adopted to collect the patient's clinical data, including current and past medical history, auxiliary examinations, pathological diagnosis, and results of genetic testing. This study was approved by the Ethics Committee of Hunan Provincial People's Hospital (Ethics No.: KY2025-150).
RESULTS:
The patient had presented with abdominal pain and abdominal mass. Imaging studies revealed ascites and space-occupying abdominal lesions. Postoperative pathological examination showed that the tumor was composed of spindle cells, and its morphology and immunohistochemistry had made it difficult to distinguish between DDLPS and leiomyosarcoma. High-throughput sequencing revealed characteristic molecular alterations of DDLPS, and fluorescence in situ hybridization confirmed MDM2 gene amplification, leading to a diagnosis of DDLPS.
CONCLUSION
The patient was diagnosed with DDLPS. Her clinical manifestations and pathological features were consistent with the characteristics of DDLPS. Molecular pathological testing played a crucial role in the diagnosis and provided a crucial reference for subsequent treatment.
Humans
;
Female
;
Adult
;
Liposarcoma/diagnosis*
;
Phenotype
;
Proto-Oncogene Proteins c-mdm2/genetics*
5.Clinical effects of Jinfukang Oral Liquid combined with thymosin α1 on patients with non-small cell lung cancer due to Dual Deficiency of Qi and Yin
Guan-jin WU ; Mo-fei HUANG ; Ao QI ; Xue-qi TIAN ; De-cai WANG ; Li-jing JIAO ; Ling XU
Chinese Traditional Patent Medicine 2025;47(3):790-795
AIM To explore the clinical effects of Jinfukang Oral Liquid combined with thymosin α1 on patients with non-small cell lung cancer due to Dual Deficiency of Qi and Yin.METHODS Seventy-five patients were randomly assigned into thymosin α1 group(15 cases)for 4-week administration,Jinfukang Oral Liquid group(30 cases)for 4-week administration,and combination group(30 cases)for 4-week administration.The changes in TCM clinical syndrome effects,immunity indices(CD3+T,Th,CTL,total NK,CD56dim CD16+NK,NKT,Treg,MDSC),lethality/inhibition ratios(CTL/Treg,total NK/Treg,NKT/Treg,CTL/MDSC,total NK/MDSC,NKT/MDSC)and FACT-L scores were detected.RESULTS The Jinfukang Oral Liquid group and combination group demonstrated higher total effective rates than the thymosin α1 group(P<0.05).After the treatment,the Jinfukang Oral Liquid group and combination group displayed increased NKT(P<0.05)and decreased MDSC(P<0.05),which were more obvious than those in the thymosin α1 group(P<0.05),and higher NKT was observable in the Jinfukang Oral Liquid group(P<0.05);the Jinfukang Oral Liquid group and combination group displayed increased lethality/inhibition ratios(P<0.05),among which NKT/Treg,CTL/MDSC,total NK/MDSC,NKT/MDSC were higher than those in the thymosin α1 group(P<0.05),and higher CTL/MDSC,NKT/MDSC were observable in the Jinfukang Oral Liquid group(P<0.05);the Jinfukang Oral Liquid group(except for physiological status,society and family status)and combination group(except for society and family status)displayed increased FACT-L scores(P<0.05).CONCLUSION For the patients with non-small cell lung cancer due to Dual Deficiency of Qi and Yin,Jinfukang Oral Liquid single use or combined with thymosin α1 can enhance peripheral blood immune surveillance,inhibit immune escape,restore the balanced state of tumor immune responses,and improve TCM syndromes and life quality.
6.Novel biallelic MCMDC2 variants were associated with meiotic arrest and nonobstructive azoospermia.
Hao-Wei BAI ; Na LI ; Yu-Xiang ZHANG ; Jia-Qiang LUO ; Ru-Hui TIAN ; Peng LI ; Yu-Hua HUANG ; Fu-Rong BAI ; Cun-Zhong DENG ; Fu-Jun ZHAO ; Ren MO ; Ning CHI ; Yu-Chuan ZHOU ; Zheng LI ; Chen-Cheng YAO ; Er-Lei ZHI
Asian Journal of Andrology 2025;27(2):268-275
Nonobstructive azoospermia (NOA), one of the most severe types of male infertility, etiology often remains unclear in most cases. Therefore, this study aimed to detect four biallelic detrimental variants (0.5%) in the minichromosome maintenance domain containing 2 ( MCMDC2 ) genes in 768 NOA patients by whole-exome sequencing (WES). Hematoxylin and eosin (H&E) demonstrated that MCMDC2 deleterious variants caused meiotic arrest in three patients (c.1360G>T, c.1956G>T, and c.685C>T) and hypospermatogenesis in one patient (c.94G>T), as further confirmed through immunofluorescence (IF) staining. The single-cell RNA sequencing data indicated that MCMDC2 was substantially expressed during spermatogenesis. The variants were confirmed as deleterious and responsible for patient infertility through bioinformatics and in vitro experimental analyses. The results revealed four MCMDC2 variants related to NOA, which contributes to the current perception of the function of MCMDC2 in male fertility and presents new perspectives on the genetic etiology of NOA.
Humans
;
Male
;
Azoospermia/genetics*
;
Meiosis/genetics*
;
Spermatogenesis/genetics*
;
Adult
;
Exome Sequencing
;
Microtubule-Associated Proteins/genetics*
;
Alleles
;
Infertility, Male/genetics*
7.Clinical analysis and literature review of 2 cases of leptospirosis in Wenchang area following super typhoon'Yagi'
Jing CHEN ; Changrui ZHENG ; Xiuying SU ; Jia TIAN ; Shan CHEN ; Wenhuang MO
Chinese Journal of Nosocomiology 2025;35(22):3400-3404
OBJECTIVE To summarize the clinical data of 2 cases of multiple organ dysfunction syndrome(MODS)induced by infection with renal leptospira so as to provide bases for prevention and control of severe dis-eases.METHODS The clinical data of the 2 patients with leptospirosis were retrospectively analyzed after the super typhoon'Yagi'on Sep.6,2024.The cases of leptospirosis that were reported at home and abroad in recent 5 years were retrieved.The epidemiological characteristics,clinical manifestations and treatment outcomes of the cases were observed.RESULTS The 2 patients began to have symptoms on the nineth day after the typhoon,both cases presented with the manifestation such as fever,pain and fatigue,shortness of breach and cough,jaundice and anu-ria,with the blood culture negative;the definite diagnosis was mased by blood metagenomic capture method(MetaCAP).The poultry was considered as the infection source,and the illness condition progressed to sepsis and MODS.Case 1 was complicated with empsyxis,jaundice hemorrhage and renal failure and finally died.Case 2 was also detected with leptospira from cerebrospinal fluid and was complicated with renal failure and meningoencephal-itis but was cured.Among 17 cases of leptospirosis from the literatures,the male and peasants were dominant,the infected water was the major infection factor(at least 7 cases);fever,pain and fatigue,shortness of breath and cough as well as hemoptysis were the major symptoms.There were at least 12 cases with the decline of plate-lets counts,10 cases complicated with empsyxis,11 cases complicated with shock and MODS and 10 cases treated with invasive mechanical ventilation.The misdiagnosis rate was up to 76.47%,and the mortality rate was 29.41%.CONCLUSIONS The leptospirosis is a severe disease,early precise antimicrobial treatment and timely or-gan function support are the crucial to the improvement of prognosis.The health care workers should attach great importance to inquiry for diagnosis,maintain vigilant to the disease for the people with fever of unknown ori-gin,shortness of breath,pain and fatigue by combining the epidemiological history,and make an early definite di-agnosis based on novel molecular diagnosis technique so as to avoid the progression to sepsis and MODS.
8.Molecular pathology assisted diagnosis of Dedifferentiated liposarcoma in a case and analyzed its clinical and genetic characteristics
Jingjing AO ; Feicheng YANG ; Yuzhong YANG ; Jia TIAN ; Chenjia LU ; Xiaoying LIU ; Zhe ZHANG ; Wenxiu YANG ; Chunjian MO
Chinese Journal of Medical Genetics 2025;42(6):741-746
Objective:To explore the clinical characteristics and genetic etiology of a patient with De-differentiated liposarcoma (DDLPS).Methods:A 38-year-old female patient with DDLPS who had visited Hunan Provincial People′s Hospital in January 2025 was selected as the study subject. A retrospective study method was adopted to collect the patient′s clinical data, including current and past medical history, auxiliary examinations, pathological diagnosis, and results of genetic testing. This study was approved by the Ethics Committee of Hunan Provincial People′s Hospital (Ethics No.: KY2025-150).Results:The patient had presented with abdominal pain and abdominal mass. Imaging studies revealed ascites and space-occupying abdominal lesions. Postoperative pathological examination showed that the tumor was composed of spindle cells, and its morphology and immunohistochemistry had made it difficult to distinguish between DDLPS and leiomyosarcoma. High-throughput sequencing revealed characteristic molecular alterations of DDLPS, and fluorescence in situ hybridization confirmed MDM2 gene amplification, leading to a diagnosis of DDLPS. Conclusion:The patient was diagnosed with DDLPS. Her clinical manifestations and pathological features were consistent with the characteristics of DDLPS. Molecular pathological testing played a crucial role in the diagnosis and provided a crucial reference for subsequent treatment.
9.Progress in human papillomavirus vaccination among men who have sex with men
Xia LUO ; Hongbin PENG ; Yinxia LIANG ; Weiyi TIAN ; Jinli MO ; Yangfang WANG ; Chuanyi NING
Chinese Journal of Microbiology and Immunology 2025;45(1):84-90
Men who have sex with men (MSM) represent a high-risk group for human papillomavirus (HPV) infection and transmission. HPV vaccination for MSM has been extensively explored in clinical trials and real-world settings in foreign countries, but it has not been widely promoted for MSM in the Chinese mainland. This article provides a comprehensive review of the HPV vaccination status among MSM, as well as the effectiveness, immunogenicity, safety, and cost-effectiveness of HPV vaccines, aiming to provide reference for the implementation and promotion of HPV vaccination among MSM in the Chinese mainland.
10.Establishment and evaluation of a CRISPR/Cas13a-based method for HBV DNA detection
Yinkang MO ; Zihao FAN ; Yuan TIAN ; Ling XU ; Yaling CAO ; Feng REN
Chinese Journal of Laboratory Medicine 2025;48(4):478-483
Objective:To construct a method for hepatitis B virus (HBV) DNA detection based on recombinase-mediated isothermal amplification (RAA)-clustered regularly interspaced short palindromic repeats and their associated protein 13a (CRISPR-Cas13a).Methods:Through the alignment and screening of HBV DNA sequences, a positive plasmid was constructed, and recombinase-aided amplification (RAA) primers and CRISPR RNA (crRNA) were designed. A method for detecting HBV DNA based on the RAA-CRISPR-Cas13a system was developed, and the specificity and sensitivity were evaluated. Utilizing the CRISPR-Cas13a system, 70 clinical samples from HBV DNA-positive patients with various viral loads collected at Beijing You′an Hospital from 2019 to 2021 were analyzed. The detection results were further compared with those results using real-time quantitative polymerase chain reaction (qPCR).Results:The optimal RAA amplification primers and crRNA were first screened using the RAA-CRISPR-Cas13a method, with the sensitivities for detecting HBV DNA standards and for clinical samples at 1 IU/ml and<10 IU/ml, respectively, demonstrating specificity for HBV DNA detection. Compared with qPCR (the gold standard), the detection consistency between the two methods was 100% (70/70).Conclusion:This study established a method for detecting HBV DNA by integrating recombinase-aided amplification (RAA) technology with CRISPR/Cas13a technology.

Result Analysis
Print
Save
E-mail